SOPHiA GENETICS Reports Financial Results for the First Quarter of Fiscal 2022

Sophia Genetics

Steady Start to 2022; FY 2022 Constant Currency Revenue Growth Guidance Reaffirmed BOSTON, United States and LAUSANNE, Switzerland, May 10, 2022 — SOPHiA GENETICS SA (Nasdaq: SOPH), a leader in data-driven medicine, today reported financial results for the first quarter ended March 31, 2022. Recent Highlights Revenue for the first quarter of 2022 was $10.9 million, …

SOPHiA GENETICS Reports Financial Results for the First Quarter of Fiscal 2022 Read More »

SOPHiA GENETICS Announces Nomination of Jean-Michel Cosséry to Board of Directorsm

Sophia Genetics

BOSTON, United States and LAUSANNE, Switzerland – May 5, 2022 – SOPHiA GENETICS (Nasdaq: SOPH), a leader in data-driven medicine, today announced the nomination of Jean-Michel Cosséry to its Board of Directors. The Board of Directors will propose the appointment of Mr. Cosséry as a member of the Board of Directors and a member of the Compensation Committee …

SOPHiA GENETICS Announces Nomination of Jean-Michel Cosséry to Board of Directorsm Read More »

LUKB selects NetGuardians for its fraud prevention systems

NetGuardians

Switzerland-based Luzerner Kantonalbank (LUKB) has selected fintech NetGuardians to improve its fraud-prevention systems. LUKB is implementing NetGuardians’ AI-based fraud-mitigation software as part of its defences against payment fraud. The software builds up accurate profiles of a bank’s customers, allowing it to spot suspicious transactions with a high degree of accuracy. This means fewer calls to customers to verify payments, …

LUKB selects NetGuardians for its fraud prevention systems Read More »

NetGuardians selected by LUKB to strengthen fraud protection

NetGuardians

Award-winning Swiss fintech NetGuardians, renowned for its enterprise risk platform for combatting financial fraud, today announced it has been selected by Luzerner Kantonalbank AG (LUKB) to further enhance its fraud-prevention systems. LUKB is implementing NetGuardians’ AI-based fraud-mitigation software as part of its defenses against payment fraud. The software builds up accurate profiles of a bank’s …

NetGuardians selected by LUKB to strengthen fraud protection Read More »

NETGUARDIANS IS SELECTED BY LUKB TO FURTHER STRENGTHEN FRAUD PREVENTION

NetGuardians

Yverdon-les-Bains, 3 May, 2022: Award-winning Swiss fintech NetGuardians, renowned for its enterprise risk platform for combatting financial fraud, today announced it has been selected by Luzerner Kantonalbank AG (LUKB) to further enhance its fraud-prevention systems. LUKB is implementing NetGuardians’ AI-based fraud-mitigation software as part of its defenses against payment fraud. The software builds up accurate profiles …

NETGUARDIANS IS SELECTED BY LUKB TO FURTHER STRENGTHEN FRAUD PREVENTION Read More »

HAYA Therapeutics Announces Funding from Swiss Innovation Agency Supporting Research Collaborations for Long Non-Coding RNA Therapies

Haya Therapeutics

New research partnerships with world-leading institutions University of Bern, University Hospital of Bern and Lausanne University Hospital Non-dilutive funding will enable the development of therapies targeting lncRNA for cardiomyopathy and squamous cell carcinoma LAUSANNE, Switzerland and SAN DIEGO – May 3, 2022 — HAYA Therapeutics, SA, a company developing precision medicines that target tissue and cell-specific long non-coding …

HAYA Therapeutics Announces Funding from Swiss Innovation Agency Supporting Research Collaborations for Long Non-Coding RNA Therapies Read More »

SPACEBEL AND CYSECSPACEBEL AND CYSEC

Cysec

The European Space Agency (ESA) awarded a contract to Spacebel (Prime contractor) and CYSEC (subcontractor) to test the secure deployment of the latest generation of European mission control software on a satellite simulator.  Cyber threats on satellite systems are more and more of a concern and are becoming a reality for satellite operators, as the recent attack …

SPACEBEL AND CYSECSPACEBEL AND CYSEC Read More »

SOPHiA GENETICS Hits Milestone of One Million Genomic Profiles Analyzed by the SOPHiA DDM™ Platform

Sophia Genetics

BOSTON, United States and LAUSANNE, Switzerland – April 26, 2022 – SOPHiA GENETICS (Nasdaq: SOPH), a leader in data-driven medicine, has reached the milestone of one million genomic profiles analyzed by its SOPHiA DDM™ Platform, securing its position as one of the largest knowledge sharing platforms connecting thousands of healthcare professionals and researchers across more than 70 countries. Founded …

SOPHiA GENETICS Hits Milestone of One Million Genomic Profiles Analyzed by the SOPHiA DDM™ Platform Read More »